JAFRAL can develop a complete production process or optimize an existing one, for both lytic and filamentous bacteriophages.
Our experience with different phages enables us to model, develop and optimize processes from petri dish to bioreactor and from lab scale purification to pilot scale production.
Optimized manufacturing processes result in high phage titers, high yields, and high purity delivered in a cost effective manner using state of the art technology with optimized upstream and downstream processes.
- T4 phage
- Lambda phage
- T7 phage
- M13 phage
JAFRAL can provide complete gene to protein service with potential protein characterization. Beginning with sequence optimization and vector construction, through best clone selection through optimization of upstream and downstream process to deliver high quality and yield protein product.
Expression systems: Bacteria, Yeast, Insects
Possible deliverables: Cell lysate, Cell paste, Filtered culture, Purified proteins
Upstream scale: Erlenmeyer Flasks, 1L, 15L, 50L, 100L, continuous
Downstream scale: downstream capabilities match the scale of fermentation. This means that one fermentation batch can be purified in a single run without the need for sub-lotting
Downstream options: IEX (Q, S), Gel filtration, Diafiltration, Reverse-phase, HIC, Affinity (Ni, Co, FLAG, Maltose, Protein A/G, Glutathione), Tag Removal and others
JAFRAL can provide various amounts of high-quality plasmid DNA from 1 mg up to 100 g for research or preclinical studies.
In recent decades a wide range of applications for plasmid DNA has been shown, initially with their use in recombinant DNA technology followed by others in areas as diverse as diagnostic, DNA vaccination and gene therapy.
JAFRAL can provide pure, homogenous, enzymatically stable phage lysins.
Phage lysins are unique anti-bacterial agents, produced by bacteriophages. They can bind to and destroy cell wall structures of bacteria that are essential for viability. Bacteria do not develop resistance as easily as with traditional antibiotic drugs.
Virus Like Particles (VLP)
JAFRAL can customize complete VLP manufacturing processes, using yeast, bacteria, or baculovirus cells.
In today’s world, new viral pathogens can spread rapidly, increasing the probability of a pandemic. Vaccines which can be rapidly and cheaply produced will be invaluable in the fight against such outbreaks. One promising new strategy is the use of virus-like particles (VLPs).
Discover The Future
Our preferred approach is to work side by side with our customers from a very early stage